SG11202000622WA - Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same - Google Patents
Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the sameInfo
- Publication number
- SG11202000622WA SG11202000622WA SG11202000622WA SG11202000622WA SG11202000622WA SG 11202000622W A SG11202000622W A SG 11202000622WA SG 11202000622W A SG11202000622W A SG 11202000622WA SG 11202000622W A SG11202000622W A SG 11202000622WA SG 11202000622W A SG11202000622W A SG 11202000622WA
- Authority
- SG
- Singapore
- Prior art keywords
- losartan
- rosuvastatin
- diabetes
- prevention
- treatment
- Prior art date
Links
- 239000002083 C09CA01 - Losartan Substances 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title 1
- 229960000528 amlodipine Drugs 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 title 1
- 229960004773 losartan Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title 1
- 229960000672 rosuvastatin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170134809 | 2017-10-17 | ||
| KR1020180112376A KR20190043076A (en) | 2017-10-17 | 2018-09-19 | Pharmaceutical composition comprising amlodipine, losartan and rosuvastatin for prevention and treatment of cardiovascular diseases accompanied by diabetes and formulated combination including the same |
| PCT/KR2018/012213 WO2019078592A1 (en) | 2017-10-17 | 2018-10-17 | Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000622WA true SG11202000622WA (en) | 2020-02-27 |
Family
ID=66174145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000622WA SG11202000622WA (en) | 2017-10-17 | 2018-10-17 | Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same |
Country Status (12)
| Country | Link |
|---|---|
| KR (1) | KR20190043076A (en) |
| CN (1) | CN111511369A (en) |
| CO (1) | CO2020001514A2 (en) |
| CR (1) | CR20200096A (en) |
| EA (1) | EA202090165A1 (en) |
| EC (1) | ECSP20014155A (en) |
| MX (1) | MX2020001681A (en) |
| NI (1) | NI202000017A (en) |
| PH (1) | PH12020500295A1 (en) |
| SG (1) | SG11202000622WA (en) |
| TW (1) | TW201922243A (en) |
| WO (1) | WO2019078592A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220664A (en) * | 2020-06-09 | 2023-03-03 | Hanmi Pharm Ind Co Ltd | COMPLEX PHARMACEUTICAL PREPARATION, TO PREVENT OR TREAT CARDIOVASCULAR DISEASES, WHICH COMPRISES AMLODIPINE, LOSARTAN AND CHLORTALIDONE IN A SINGLE-LAYER TABLET |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100742432B1 (en) | 2005-12-27 | 2007-07-24 | 한미약품 주식회사 | Complex formulation comprising amlodipine camsylate and simvastatin, and method for preparation thereof |
| KR100888131B1 (en) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | Combination preparation for Cardiovascular disease therapy by Chronotherapy theory. |
| SG10201507488RA (en) * | 2007-03-21 | 2015-10-29 | Sigma Tau Ind Farmaceuti | Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance |
| KR101207618B1 (en) * | 2008-02-22 | 2012-12-04 | 한올바이오파마주식회사 | Pharmaceutical formulation for treating cardiovascular disease |
| KR101910901B1 (en) * | 2013-11-29 | 2018-10-24 | 한미약품 주식회사 | Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin |
| CN112933093A (en) * | 2015-06-30 | 2021-06-11 | 韩美药品株式会社 | Pharmaceutical composite preparation containing amlodipine, losartan and rosuvastatin |
-
2018
- 2018-09-19 KR KR1020180112376A patent/KR20190043076A/en active Search and Examination
- 2018-10-16 TW TW107136415A patent/TW201922243A/en unknown
- 2018-10-17 EA EA202090165A patent/EA202090165A1/en unknown
- 2018-10-17 MX MX2020001681A patent/MX2020001681A/en unknown
- 2018-10-17 CR CR20200096A patent/CR20200096A/en unknown
- 2018-10-17 SG SG11202000622WA patent/SG11202000622WA/en unknown
- 2018-10-17 WO PCT/KR2018/012213 patent/WO2019078592A1/en active Application Filing
- 2018-10-17 CN CN201880081280.XA patent/CN111511369A/en not_active Withdrawn
-
2020
- 2020-02-10 PH PH12020500295A patent/PH12020500295A1/en unknown
- 2020-02-11 CO CONC2020/0001514A patent/CO2020001514A2/en unknown
- 2020-02-26 EC ECSENADI202014155A patent/ECSP20014155A/en unknown
- 2020-02-28 NI NI202000017A patent/NI202000017A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2020001514A2 (en) | 2020-02-28 |
| CN111511369A (en) | 2020-08-07 |
| ECSP20014155A (en) | 2020-04-22 |
| MX2020001681A (en) | 2020-07-13 |
| TW201922243A (en) | 2019-06-16 |
| CR20200096A (en) | 2020-04-03 |
| WO2019078592A1 (en) | 2019-04-25 |
| PH12020500295A1 (en) | 2020-11-09 |
| KR20190043076A (en) | 2019-04-25 |
| EA202090165A1 (en) | 2020-07-10 |
| NI202000017A (en) | 2020-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3453707T1 (en) | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | |
| EP3481402A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
| IL255509B (en) | Compounds as ccr2 modulators, pharmaceutical compositions comprising same and their use for the treatment of diseases | |
| EP3370748A4 (en) | Therapeutic microbiota for the treatment and/or prevention of food allergy | |
| EP3484504A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
| EP3411504A4 (en) | Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes | |
| IL254098A0 (en) | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | |
| IL272446A (en) | Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | |
| EP3231436A4 (en) | Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient | |
| HUE055181T2 (en) | Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin | |
| GB201518456D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases | |
| EP3294313A4 (en) | Methods relating to the prevention and treatment of drug resistance | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| IL251392A0 (en) | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes | |
| SG11202000622WA (en) | Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same | |
| IL262929B1 (en) | Composition, and application and pharmaceutical preparation thereof | |
| GB2568928B (en) | Neuroprotective composition, preparation process thereof and medical uses thereof | |
| EP3534924A4 (en) | Composition for the prevention and/or treatment of cardiovascular diseases | |
| EP3690054A4 (en) | Pharmaceutical composition for prevention or treatment of heart failure | |
| WO2017075484A3 (en) | Highly potent antibodies binding to death receptor 4 and death receptor 5 | |
| EP2924024A3 (en) | Solid forms of lorcaserin hydrochloride | |
| HUE056766T2 (en) | Ethynyl compounds, their preparation and their therapeutic use for the treatment of malaria |